Activated protein C inhibits chemotaxis and interleukin-6 release by human neutrophils without affecting other neutrophil functions

British Journal of Anaesthesia

Volumn 100, Issue 6, 2008, Pages 815-819

  Galley, H F ^a   El Sakka, N E ^a,c   Webster, N R ^a   Lowes, D A ^a   Cuthbertson, B H ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Blood, coagulation; Blood, neutrophils; Complications, septicaemia

Indexed keywords

CYTOKINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOCORTIN 5; LIPOPOLYSACCHARIDE; PLASMINOGEN ACTIVATOR INHIBITOR 3;

ADULT; APOPTOSIS; ARTICLE; CELL SELECTION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; MALE; MIGRATION; NEUTROPHIL CHEMOTAXIS; NORMAL HUMAN; PRIORITY JOURNAL; RESPIRATORY BURST; STATISTICAL SIGNIFICANCE;

EID: 44649103920     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen079     Document Type: Article

References (29)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10
2. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
3. Brown KA, Brain SD, Pearson JD, et al. Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368: 157-69
4. Galley HF, Dubbels AM, Webster NR. The effect of midazolam and propofol on interleukin-8 from human polymorphonuclear leukocytes. Anesth Analg 1998; 86: 1289-93
5. Macia WL, Dhainaut JF, Yan SB, et al. Pharmacokinetic- pharmacodynamic analysis of drotrecogin alfa (activated) (recombinant human activated protein C) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72: 391-401
6. Elsakka N, Galley HF, Sharaki O, et al. Delayed apoptosis in patients with multiple organ dysfunction. Crit Care Shock 2006; 9: 9-15
7. Smith JA, Wiedemann MJ. Further characterization of the neutrophil oxidative burst by flow cytometry. J Immunol Methods 1993; 162: 261-8
8. Blaylock MG, Cuthbertson BH, Galley HF, et al. The effect of nitric oxide and peroxynitrite on apoptosis in human polymorphonuclear leukocytes. Free Rad Biol Med 1998; 25: 748-52
9. Rice TW, Bernard GR. Therapeutic interventions and targets for sepsis. Ann Rev Med 2005; 56: 225-48
10. Haley M, Xizhong C, Minneci PC, et al. Recombinant human activated protein C in sepsis: assessing its clinical use. Am J Med Sc 2004; 328: 215-9
11. Abraham E. Effects of recombinant human activated protein C in human models of endotoxin administration. Proc Am Thorac Soc 2005; 2: 243-7
12. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32: 49-60
13. Sturn DH, Kaneider NC, Feistritzer C, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003; 102: 1499P-1505P
14. Crimi E, Sica V, Williams-Ignarro S, et al. The role of oxidative stress in adult critical care. Free Radic Biol Med 2006; 40: 398-406
15. MacDonald J, Galley HF, Webster NR. Oxidative stress and gene expression in sepsis. Br J Anaesth 2003; 90: 221-32
16. Mishra V. Oxidative stress and role of antioxidant supplementation in critical illness. Clin Lab 2007; 53: 199-209
17. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Jmmunol 2006; 177: 2115-22
18. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373: 65-70
19. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104: 3878-85
20. Czeslick EG, Nestler F, Simm A, Struppert A, Sablotzki A. Drotrecogin alfa (activated) does not affect intracellular production of interleukin-6 and tumor necrosis factor-alpha in endotoxin-stimulated human monocytes. Anesth Analg 2005; 101: 1805-8
21. Nielsen JS, Larsson A, Rix T, et al. The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia. Intensive Care Med 2007; 33: 1085-93
22. Damas D, Ledoux M, Nys M, et al. Cytokine serum level during severe sepsis in human: IL-6 as a marker of severity. Ann Surg 1992; 215: 356-62
23. Li Y. Up-regulation interleukin-6 and interleukin-8 by activated protein C in lipopolysaccharide-treated human umbilical vein endothelial cells. J Zhejiang Univ Sci B 2006; 7: 899-905
24. White B, Schmidt M, Murphy C, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000; 110: 130-4
25. Brueckmann M, Hoffmann U, Dvortsak E, et al. Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 2004; 53: 528-33
26. Bohrer H, Qiu F, Zimmermann T, et al. Role of NFkappaB in the mortality of sepsis. J Clin Invest 1997; 100: 972-85
27. Arnalich F, Garcia-Palomero E, Lopez J, et al. Predictive value of nuclear factor kappa B activity and plasma cytokine levels in patients with sepsis. Infect Immun 2000; 68: 1942-5
28. Paterson RL, Galley HF, Dhillon JK, Webster NR. Increased nuclear factor kappa B activation in critically ill patients who die. Crit Care Med 2000; 28: 1047-51
29. Paterson RL, Galley HF, Webster NR. The effect of N-acetylcysteine on nuclear factor κB activation, interleukin-6, interleukin-8 and intercellular adhesion molecule-1 expression in patients with sepsis. Crit Care Med 2003; 31: 2574-8